AI assistant
BioXcel Therapeutics, Inc. — Director's Dealing 2025
Sep 17, 2025
34564_dirs_2025-09-16_b86cd723-f4ce-44a2-ab3a-e3ee784d3506.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2025-09-14
Reporting Person: Steinhart Richard I (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-14 | Common Stock | M | 33 | — | Acquired | 6474 | Direct |
| 2025-09-15 | Common Stock | M | 35 | — | Acquired | 6509 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-09-14 | Restricted Stock Units | $ | M | 33 | Disposed | Common Stock (33) | Direct | |
| 2025-09-15 | Restricted Stock Units | $ | M | 35 | Disposed | Common Stock (35) | Direct |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
F3: On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.